Background: Treatment adherence (TA) is crucial during almost any phase of bipolar disorder (BD), including type-II (BD-II) acute depression. While a number of issues have been traditionally accounted on the matter, additional factors should be likewise involved, including affective temperaments and some clinically suggestive psychopathological traits whose systematic assessment represents the aim of this study. Methods: Two hundred and twenty BD-II acute depressed outpatients were consecutively evaluated using the Structured Clinical Interviews for Diagnostic and Statistical Manual for Mental Disorders-Fourth Edition Axis-I and II Disorders, Hamilton scales for Depression and Anxiety, Temperament Evaluation of the Memphis Pisa Paris San Diego-Auto-questionnaire-110-item, Visual Analogue Scale (VAS), Zuckerman's Sensation Seeking Scale-Form-V (SSS-V), Barratt's Impulsivity Scale-11-item, State Trait Anxiety Inventory modules, Severity module of the Clinical Global Impression Scale for BD, Morisky 8-Item Medication Adherence Scale (MMAS-8) and the Clinician Rating Scale (CRS). Patients were divided into non adherent vs. treatment adherent cases depending on MMAS-8+CRS scores. Results: In the TA(-) group, higher VAS and cyclothymic temperament scores were highly correlated (r=.699; p <=.001). Those latter scores, along with SSS-V scores and the occurrence of lifetime addiction to painkiller and/or homeopathic medications available over the counter defined a "therapeutic sensation seeking" pattern allowing to correctly classify as much as 93.9% [Exp(B)=3.490; p <=.001] of TA(-) cases (49/220). Limits: Lick of objective TA measures and systematic pharmacological record; recall bias on some diagnoses; and relatively small sample size. Conclusions: Stating the burden of TA in BD, additional studies on this regard are aimed, ideally contributing to enhance the management of BD itself., (C) 2013 Elsevier B.V. All rights reserved.
Treatment adherence towards prescribed medications in bipolar-II acute depressed patients: Relationship with cyclothymic temperament and "therapeutic sensation seeking" in response towards subjective intolerance to pain
Ventriglio A;
2013-01-01
Abstract
Background: Treatment adherence (TA) is crucial during almost any phase of bipolar disorder (BD), including type-II (BD-II) acute depression. While a number of issues have been traditionally accounted on the matter, additional factors should be likewise involved, including affective temperaments and some clinically suggestive psychopathological traits whose systematic assessment represents the aim of this study. Methods: Two hundred and twenty BD-II acute depressed outpatients were consecutively evaluated using the Structured Clinical Interviews for Diagnostic and Statistical Manual for Mental Disorders-Fourth Edition Axis-I and II Disorders, Hamilton scales for Depression and Anxiety, Temperament Evaluation of the Memphis Pisa Paris San Diego-Auto-questionnaire-110-item, Visual Analogue Scale (VAS), Zuckerman's Sensation Seeking Scale-Form-V (SSS-V), Barratt's Impulsivity Scale-11-item, State Trait Anxiety Inventory modules, Severity module of the Clinical Global Impression Scale for BD, Morisky 8-Item Medication Adherence Scale (MMAS-8) and the Clinician Rating Scale (CRS). Patients were divided into non adherent vs. treatment adherent cases depending on MMAS-8+CRS scores. Results: In the TA(-) group, higher VAS and cyclothymic temperament scores were highly correlated (r=.699; p <=.001). Those latter scores, along with SSS-V scores and the occurrence of lifetime addiction to painkiller and/or homeopathic medications available over the counter defined a "therapeutic sensation seeking" pattern allowing to correctly classify as much as 93.9% [Exp(B)=3.490; p <=.001] of TA(-) cases (49/220). Limits: Lick of objective TA measures and systematic pharmacological record; recall bias on some diagnoses; and relatively small sample size. Conclusions: Stating the burden of TA in BD, additional studies on this regard are aimed, ideally contributing to enhance the management of BD itself., (C) 2013 Elsevier B.V. All rights reserved.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
